Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 9:58 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 25,172 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: PRE Clear all

Conditions: Neuroendocrine Tumors
Interventions: Satoreotide tetraxetan, Amino acid solution, Antiemetic; Drug · Other
Lead sponsor: Ipsen; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Lymphoma
Interventions: Obinutuzumab, Glofitamab, Rituximab, Bendamustine, Lenalidomide, Tocilizumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 25
States / cities: Berkeley, California • Duarte, California • Los Angeles, California + 22 more

Conditions: Pre-Exposure Prophylaxis
Interventions: Probenecid Oral Tablet, Tenofovir disoproxil fumarate/Emtricitabine; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Depression - Major Depressive Disorder, Anxiety, Stress
Interventions: Digital Physical Activity; Behavioral
Lead sponsor: Auburn University; Other
Eligibility: 19 Years to 40 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Auburn, Alabama

Conditions: Breast Cancer
Interventions: KIBUR MICRODEVICE, anthracycline and taxane based chemotherapy; Device · Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 19 Years and older · Female only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 6
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 3 more

Conditions: Acute Myelogenous Leukemia, Ovarian Cancer, Colorectal Cancer, Triple-negative Breast Cancer, Small-cell Lung Cancer
Interventions: galinpepimut-S, pembrolizumab, Montanide, GM-CSF; Biological · Other
Lead sponsor: Sellas Life Sciences Group; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 12
States / cities: Santa Rosa, California • Whittier, California • Miami, Florida + 9 more

Conditions: C. Difficile
Interventions: Arm 1: Routine care, Arm 2: Preemptive C. difficile infection prevention bundle; Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 261 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Graft vs. Host Disease
Interventions: Obinutuzumab, Placebo; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 181 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 5
States / cities: Palo Alto, California • Boston, Massachusetts • Minneapolis, Minnesota + 1 more

Conditions: Metastatic Breast Cancer, Locally Advanced Breast Cancer
Interventions: Gemcitabine, Bevacizumab; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 16
States / cities: Fayetteville, Arkansas • Fresno, California • San Diego, California + 13 more

Conditions: CKD Stage 3/4
Interventions: Vitamin D 2mg daily for 2 weeks oral paricalcitol, Placebo; Drug
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Malaria
Interventions: Chloroquine Phosphate, Pyrimethamine, Sanaria PfSPZ Challenge; Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Bronchitis, Sinusitis, Urinary Tract Infections
Interventions: Fluoroquinolone (FQ), Azithromycin (AZ), Sulfamethoxazole/Trimethoprim (ST) Fixed Dose Combination; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 239,306 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Titusville, New Jersey

Conditions: Cardiometabolic Syndrome, Type 2 Diabetes, Sleep, Time Restricted Feeding, Lifestyle Factors, Overweight and Obesity, Insulin Sensitivity, Eating Habit, Sleep Hygiene
Interventions: Circadian Intervention; Behavioral
Lead sponsor: University of Utah; Other
Eligibility: 18 Years to 45 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Type 2 Diabetes Mellitus
Interventions: Diabetes MESSAGES Program, Diabetes MESSAGES Program (second trial); Other
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 265 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Frailty, Thoracic, Prehabilitation, Lung Surgery, Wedge Resection, Segmentectomy, Lobectomy, Pneumonectomy; Status
Interventions: Auricular Acupressure; Other
Lead sponsor: University of Chicago; Other
Eligibility: 50 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Rectal Adenocarcinoma, Rectal Cancer
Interventions: High Rare Dose Rectal Brachytherapy Boost; Radiation
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 100 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 3
States / cities: Aurora, Colorado • Rochester, New York • Portland, Oregon

Conditions: Gender Dysphoria, Gender Dysphoria, Adult, Gender Incongruence, Transgenderism, Transsexualism, Transgender Persons, Phalloplasty
Interventions: MaPS Decision Aid; Behavioral
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 2
States / cities: Hanover, New Hampshire • Salt Lake City, Utah

Conditions: Labor Pain
Interventions: Sterile normal saline 0 mls, 15 mls sterile normal saline; Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 12 Years and older · Female only
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Carpal Tunnel Syndrome
Interventions: lidocaine patch 5%; Drug
Lead sponsor: Endo USA Inc., a Keenova Therapeutics Company; Industry
Eligibility: 18 Years and older
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Critical Illness, Acute Respiratory Distress Syndrome, Septic Shock
Interventions: Telehealth; Other
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Hepatocellular Carcinoma
Interventions: ICG, Optical molecular imaging; Biological · Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Functional Gastrointestinal Disorders
Interventions: Clinical Decision Support; Behavioral
Lead sponsor: Indiana University; Other
Eligibility: 1 Day to 17 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Sensory Processing Dysfunction
Interventions: Not listed
Lead sponsor: The Spiral Foundation at OTA Watertown; Other
Eligibility: 13 Years to 95 Years
Enrollment: 1,300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Newton, Massachusetts

Conditions: Non - Small Cell Lung Cancer NSCLC
Interventions: MEDI4736 (durvalumab), Vinorelbine, Gemcitabine, Erlotinib, MEDI4736 (durvalumab) in combination with tremelimumab (anti-CTLA4), tremelimumab (anti-CTLA4); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 597 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 33
States / cities: Chandler, Arizona • Anaheim, California • Duarte, California + 29 more

Search by objective public record fields.

Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs

A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma

Assessment of a New "Boosting" Strategy for HIV Pre-exposure Prophylaxis in Healthy Volunteers

Digital Intervention for Physical Activity

Implantable Microdevice for In Vivo Drug Sensitivity Testing in Patients With Early Stage, HER2-Positive or Triple Negative Breast Cancer

Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers

Pre-emptive Prevention for Patients at High Risk for Hospital-onset Clostridioides Difficile

Obinutuzumab in cGVHD After Allogeneic Peripheral Blood Stem Cell Transplantation

Gemcitabine Plus Bevacizumab in Locally Recurrent or Metastatic Breast Cancer

Identification of Markers for Determining the Efficacy of Vitamin D Receptor Activator Therapy in Stage 3/4 CKD Patients

Dose Escalation PfSPZ-CVac

Fluoroquinolone Associated Disability

Circadian Intervention to Improve Cardiometabolic Health

Medical Care, Education, Social Support, And Goal-setting to Empower Self-management for Diabetes

Auricular Acupressure in Prehabilitation

Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

Metoidioplasty and Phalloplasty Surgery Decision Making

Combined Spinal/Epidural (CSE) Saline Duration/Spread

Safety and Efficacy of Lidoderm (Lidocaine Patch 5%) in Treating Moderate to Severe Pain Associated With Carpal Tunnel Syndrome

TelePORT Pilot Study

A Pilot Study of Optical Molecular Imaging for Percutaneous Biopsy of Hepatocellular Carcinoma Using Indocyanine Green

Systematic Pediatric Assessment of Rome Criteria (SPARC)

Sensory Processing Difficulties in Adults and Adolescents

A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer